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Preoperative prediction of mortality within 1 year
after elective thoracic endovascular aortic
aneurysm repair
Salvatore T. Scali, MD,a Catherine K. Chang, MD,a Robert J. Feezor, MD,a Philip J. Hess Jr, MD,b
Thomas M. Beaver, MD, MPH,b Tomas D. Martin, MD,b Thomas S. Huber, MD, PhD,a and
Adam W. Beck, MD,a Gainesville, Fla
Objective: Thoracic endovascular aortic repair (TEVAR) is known to have a survival benefit over open repair in patients
with descending thoracic aneurysms and has become a mainstay of therapy. Because death before 1 year after TEVAR
likely indicates an ineffective therapy, we have created a predictive model for death within 1 year using factors available
in the preoperative setting.
Methods:A registry of 526 TEVARs performed at the University of Florida between September 2000 andNovember 2010
was queried for patients with degenerative descending thoracic aneurysm as their primary pathology. Procedures with
emergent or urgent indications were excluded. Preoperatively available variables, such as baseline comorbidities,
anatomic-, and procedure-specific planning details, were recorded. Univariate predictors of death were analyzed with
multivariable Cox proportional hazards to identify independent predictors of 30-day (death within 30 days) and 1-year
mortality (death within 1 year) after TEVAR.
Results: A total of 224 patients were identified and evaluated. The 30-day mortality rate was 3% (n  7) and the 1-year
mortality rate was 15% (n  33). Multivariable predictors of 1-year mortality (hazard ratios [95% confidence interval])
included: age>70 years (5.8 [2.1-16.0]; P .001), adjunctive intraoperative procedures (eg, brachiocephalic or visceral
stents, or both, concomitant arch debranching procedures; 4.5 [1.9-10.8]; P  .001), peripheral arterial disease (3.0
[1.4-6.7]; P  .006), coronary artery disease (2.4 [1.1-4.9]; P  .02), and chronic obstructive pulmonary disease (1.9
[1.0-3.9]; P .06). A diagnosis of hyperlipidemia was protective (0.4 [0.2-0.7]; P .006). When patients were grouped
into those with one, two, three, or four or more of these risk factors, the predicted 1-year mortality was 1%, 3%, 10%, 27%,
and 54%, respectively.
Conclusions: Factors are available in the preoperative setting that are predictive of death within 1 year after TEVAR and
can guide clinical decision making regarding the timing of repair. Patients with multiple risk factors, such as age >70
years, coronary artery disease, chronic obstructive pulmonary disease, and a need for an extensive procedure involving
adjunctive therapies, have a high predicted mortality within 1 year and may be best served by waiting for a larger
aneurysm size to justify the risk of intervention. (J Vasc Surg 2012;56:1266-73.)
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fOne of the greatest challenges that any surgeon must
face is performing high-risk interventions for prophylactic
indications, and this is certainly true in the management of
aneurysmal disease of the thoracic aorta. With the U.S.
Food and Drug Administration’s approval of thoracic en-
dovascular aortic repair (TEVAR) for descending thoracic
aneurysms (DTAs) in 2005, a rapid adoption of this tech-
nology has led to TEVAR becoming a mainstay of treat-
ment.1-4 TEVAR quickly supplemented open surgical re-
construction by expanding the patient population for
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1266hich repair is considered.2 The finding that TEVAR has
ugmented the total number of repairs instead of supplant-
ng open surgical reconstruction is in some ways explained
y the favorable short-term and midterm outcomes of
EVAR in “high-risk” or “no-option” patients.5,6
Multiple studies have demonstrated the perioperative
enefit of TEVAR over open surgical treatment,4,7,8 and
he longer-term survival benefit is generally placed in the
ontext of 5-year survival. Although perioperative or 30-
ay mortality rates may demonstrate the safety of TEVAR,
hey do not define late benefit. Similarly, 5-year survival is
ften related to other comorbidities, such as cardiac dis-
ase, malignancy, or cerebrovascular occlusive disease,
ather than to a benefit of TEVAR itself. Clinical decision
aking and patient counseling regarding the timing of
ntervention tend to focus on the 1-year rupture and dis-
ection risk, against which the risk of intervention and the
atient’s anticipated life expectancy are weighed. Most
urgeons would agree that death1 year after a prophylac-
ic intervention defines an ineffective or unnecessary treat-
ent. This concept was previously described by Beck et al9
or open and endovascular (EVAR) repair of infrarenal
bdominal aortic aneurysms (AAAs). Although open AAA
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Volume 56, Number 5 Scali et al 1267repair had multiple risk predictors for death within 1 year
after repair, EVAR had few predictors of death.
Although one might be tempted to assume that the
1-year outcomes after TEVAR would mirror those of
EVAR, DTA patients frequently have more advanced co-
morbidities than their counterparts with infrarenal AAAs
and are known to have poorer long-term survival than AAA
patients.10 In addition, the 1-year mortality rate after TE-
VAR for intact aneurysms ranges from 10% to 18%,11,12
which is considerably higher than the 4% to 12% reported
after EVAR.13,14
With the idea that death within 1 year after TEVAR
performed in the elective setting indicates an ineffective or
unnecessary therapy, the purpose of this study was to create
a predictive model for mortality within 1 year after TEVAR
using preoperatively available risk factors. Such a prediction
model can help guide clinical decision making by identify-
ing patients who would benefit most from intervention as
well those patients with shorter life expectancy who might
be better served with medical management or waiting for a
larger aneurysm diameter (ie, rupture risk) to justify repair.
METHODS
Approval for this study was obtained from the Institu-
tional Review Board at the University of Florida College of
Medicine.
Patients and database. A dedicated, prospectively
maintained endovascular aortic registry is kept at the Uni-
versity of Florida containing all patients who have under-
gone EVAR and TEVAR. This database contains 50
patient- and procedure-specific variables that are entered by
the operating surgeon for each patient at the time of
operation. The database undergoes scheduled quality-
control audits by study coordinators working within the
division. In addition, data within the registry are routinely
updated and augmented by complete review of the medical
record. Any additional data required for this analysis were
obtained by data abstraction from the patient’s electronic
medical record.
Additional covariates that were aggregated included
preoperative American Society of Anesthesiologists (ASA)
Physical Status Classification system score15,16 as well as
antiplatelet, anticoagulant, and -blocker use. Also re-
corded were procedural characteristics such as landing
zone, need for procedural adjuncts, spinal drain use, post-
operative complications, endoleak, and need for reinterven-
tion. Aneurysm diameters were measured using centerline
measurements obtained from a three-dimensional recon-
struction performed with a TeraRecon Aquarius Worksta-
tion (TeraRecon Inc, Foster City, Calif). Patient deaths
were confirmed using the Social Security Death Index.
The database was queried for patients with degenera-
tive DTA as their primary pathology. Procedures com-
pleted for dissection and urgent or emergency indications
were excluded. The analysis excluded patients categorized
in the database as having thoracoabdominal aneurysms or
patients undergoing visceral debranching; however, pa-
tients requiring brachiocephalic debranching (eg, carotid-o-subclavian bypass) or adjunctive stenting to provide
roximal or distal landing zones were included.
Risk model design. The primary outcome was 1-year
ortality (defined as death within 1 year of TEVAR) and
he secondary outcome was 30-day mortality (similarly
efined as death within 30 days of TEVAR). Only
ollow-up data within 1 year of repair were used in the
evelopment of the model to predict the primary outcome.
urvival was estimated using life-table analysis.
A univariate Cox proportional hazard model was used
o identify preoperative risk factors associated with time to
eath within 1 year after TEVAR. The analysis incorpo-
ated follow-up data from time of surgery up to 1 year after
EVAR. Preoperative risk factors found on univariate anal-
sis to have a value of P  .2 were included in the multi-
ariable model, which was developed using stepwise back-
ard Cox regression. Log-likelihoods were compared with
nd without inclusion of each predictor in the multivari-
ble model and only included in the final model if the
ikelihood-ratio test P value was .1.
Hazard ratios (HRs) and corresponding 95% confi-
ence intervals (CIs) for postoperative death within 1 year
f TEVAR were estimated from the multivariable model.
ox-Snell residuals were used to predict 1-year mortality
or death occurring within 1 year of repair) based on each
atient’s profile of preoperative risk factors. All statistical
nalysis was performed using Stata 11 software (StataCorp,
ollege Station, Tex).
Definitions. Comorbidities were defined and re-
orded as follows:
● Coronary artery disease (CAD): any history of myocar-
dial infarction, angina, coronary intervention, or elec-
trocardiograph changes consistent with prior myocar-
dial infarction;
● Cerebrovascular occlusive disease (CVOD): any his-
tory of transient ischemic attack, stroke, or prior ca-
rotid endarterectomy or stent;
● Congestive heart failure: medical record history, New
York Heart Association functional classII, or preop-
erative evaluation;
● Chronic obstructive pulmonary disease (COPD):
medical record history or preoperative pulmonary
function testing consistent with the diagnosis;
● Diabetes mellitus: medical record history, requiring
insulin or noninsulin drugs;
● Chronic renal insufficiency: creatinine 1.8 mg/dL;
● End-stage renal disease: on dialysis;
● Peripheral arterial disease (PAD): ankle-brachial index
0.9, medical record history, prior peripheral endo-
vascular intervention or open infrainguinal reconstruc-
tion;
● Hypertension: medical record history, on antihyper-
tensive medications or preoperative blood pressure
140/90 mm Hg;
● Dyslipidemia: medical record history, on cholesterol-
lowering medications;● History of aortic surgery.
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Between September 2000 and November 2010, 526
TEVARs were performed at the University of Florida. On
the basis of the inclusion and exclusion criteria outlined
above, 224 patients were identified and further analyzed.
Patient demographics are outlined in Table I. Median
follow-up for the 224 patients was 27.6 months (range,
0-121; interquartile range, 9.6-48.8 months). Among pa-
tients who did not die within 1 year of TEVAR, 82% had
1 year of follow-up.
TEVAR mortality. The overall 30-day and 1-year
mortality rates were 3% (n  7) and 15% (n  33),
respectively (Fig 1). Univariate predictors of 1-year mortal-
ity, defined as death within 1 year of repair, included age
70 years (P  .005), CAD (P  .04), congestive heart
failure (P  .009), PAD (P  .004), CVOD (P  .07),
COPD (P  .07), aneurysm diameter (P  .07), the need
for adjunctive procedures (P  .004), and hyperlipidemia
(P  .2).
By multivariable analysis, factors independently associ-
ated with 1-year mortality included age 70 years (HR,
5.8; 95% CI, 2.1-16.0; P .001), adjunctive intraoperative
procedures (eg, brachiocephalic or visceral stents, concom-
itant arch debranching procedures; HR, 4.5; 95% CI, 1.9-
10.8; P  .001), PAD (HR, 3.0; 95% CI, 1.4-6.7; P 
.006), CAD (HR, 2.4; 95% CI, 1.1-4.9; P  .02), and
COPD (HR, 1.9; 95% CI, 1.0-3.9; P .06). A diagnosis of
hyperlipidemia was protective (HR, 0.4; 95% CI, 0.2-0.7;
P  .006; Table II).
Patients were categorized by the number of preopera-
tive risk factors present in any combination. Patients with
four or more risk factors were grouped because few patients
had four or five risk factors and no patient had all six. The
observed 30-day and 1-year mortality after TEVAR is
Table I. Patient demographics
Variable
Mean  SD or %
(N  224)
Age, years 60.6  0.5
Male sex 62.7
Aneurysm diameter, cm 6.25  1.33
Comorbidities
Hypertension 85
Dyslipidemia 51
CAD 38
COPD 28
Diabetes mellitus 14
PVOD 12
CRI (creatinine 1.8 mg/dL) 11
Congestive heart failure 7
ASA 4 67
Antiplatelet use 80
Statin use 55
Intraoperative adjunct 9
ASA, American Society of Anesthesiologists; CAD, coronary artery disease;
COPD, chronic obstructive pulmonary disease; CRI, chronic renal insuffi-
ciency; PVOD, peripheral vascular occlusive disease; SD, standard deviation.shown in Fig 2. Patients with one risk factor had 0% wortality rate at 30 days with elective TEVAR and a 1.5%
ortality rate within 1 year. In sharp contrast, patients with
our or more risk factors had 19% mortality at 30 days and
0% mortality within 1 year. Of note, 67% of the observed
eaths at 1 year after TEVAR occurred after the perioper-
tive period (Fig 3).
Prediction of death within 1 year and model
alidation. In the multivariable model, predicted 1-year
ortality ranged from 0.9% with no risk factors up to 54.2%
ith four or more risk factors. When stratified by zero to
ne (n  78; 35%), two (n  81; 36%), three (n  48;
2%), or four or more risk factors (n  16; 7%), the
redicted 1-year mortality was 3%, 10%, 27%, and 54%,
espectively (Fig 4). Discrimination of the model was as-
essed with calculation of the C index, or probability that
redictions and outcomes are concordant, which ranges
rom 0.5 (no discrimination) to 1.0 (perfect discrimina-
ion). The C index of the multivariable model for mortality
ig 1. Kaplan-Meier curve is presented with the life table for all
atients after thoracic endovascular aortic repair (TEVAR) for a
escending thoracic aneurysm (DTA). All displayed intervals have
10% standard error of the mean.
able II. Multivariable predictors of mortality within 1
ear after TEVAR for descending thoracic aortic
neurysm identified by multivariate Cox proportional
azards model
isk factor HR (95% CI) P
ge 70 years 5.8 (2.1-16.0) .001
djunctive proceduresa 4.5 (1.9-10.8) .001
eripheral vascular disease 3.0 (1.4-6.7) .006
AD 2.4 (1.1-4.9) .02
OPD 1.9 (1.0-3.9) .06
yperlipidemia history 0.4 (0.2-0.7) .006
AD,Coronary artery disease;CI, confidence interval;COPD, chronic obstructive
ulmonary disease;HR, hazard ratio;TEVAR, thoracic endovascular aortic repair.
Adjunctive procedures: carotid-subclavian bypass, iliac conduit, visceral or
rachiocephalic stenting.ithin 1 year of TEVAR was satisfactory at 0.77. Calibra-
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a plot of predicted vs observed events and was acceptable,
with a slope of 0.94 and an intercept of 0.6% (slope of 1 and
intercept of 0 representing perfect calibration).
Diameter of DTA at time of repair. To determine if
surgeons are taking risk factors into account when consid-
ering timing of repair, patients were evaluated for aneurysm
diameter at the time of operation and categorized by the
absolute number of risk factors for death within 1 year.
Mean diameter was 55 mm for patients with no indepen-
dent risk factors for death within 1 year of repair and 70 mm
for patients with four or more risk factors. A linear trend
was found between the number of risk factors and the mean
aneurysm size at time of repair (P  .03; Fig 5).
DISCUSSION
Many reports have documented univariate predictors
for mortality after TEVAR.4-6,17 However, the current
study is the first to identify independent variables that can
be assessed preoperatively to develop a risk score to facili-
tate clinical decision making and patient counseling. Peri-
operative variables associated with death included age70
years, requirement for an intraprocedural adjunct, PAD,
CAD, and COPD. A preoperative diagnosis of hyperlipid-
emia, presumptively a surrogate for statin use, was protec-
tive.
Elective DTA repair is only beneficial when aneurysm
rupture or dissection is likely to occur during the patient’s
lifetime; therefore, surgeons must consider patient life ex-
pectancy when they select appropriate candidates for DTA
repair. Most surgeons agree that if a patient’s life expec-
tancy is too short to gain benefit from a prophylactic
intervention, the therapy should be considered ineffective
or unnecessary.9 Patient discussions regarding risk of an
unrepaired DTA are usually placed into the context of
1-year aortic complication risk. The annual risk of aortic-
related complications secondary to DTA rapidly increases
Fig 2. Thirty-day vs 1-year mortality after thoracic endovascular
aortic repair (TEVAR) stratified by risk factor group shows that most
deaths within 1 year occurred beyond the first 30 days after repair.after 6 cm in size.10 Thus, current recommendations are shat aneurysms of the DTA be repaired at6.0 cm.18 Most
ould consider that elective treatment is an ineffective or
nnecessary intervention when death occurs within 1
ear. This study demonstrates that some patients have a
uch higher risk of death within 1 year of repair and that
erhaps diameter of repair should be a moving target
ith relation to a patient’s risk of death within 1 year
fter TEVAR.
The minimally invasive nature of TEVAR has provided
ower perioperative morbidity and mortality compared with
n open operation,1,3,4,12 and the number of patients
eemed eligible for repair has expanded greatly without
trong evidence for longer-term benefit.11 Despite the
erioperative advantage of TEVAR, the all-cause mortality
ithin 1 year for the elective endovascular management of
TA has been documented to range from 10% to
8%,3,11,12 which is consistent with our results (Fig 1).
ith relatively low 30-day major morbidity and mortality,
he sobering 1-year mortality outcomes after TEVAR fur-
her emphasizes the need to understand what patient pop-
lations will be best served with prophylactic intervention.
As endovascular therapies continue to be offered to
igh-risk patients and the risk-to-benefit ratio becomes less
ramatic, a call for comparative effectiveness research and
evelopment of regional quality improvement registries has
een made to address this issue.19 To this end, improved
ecision-making algorithms and patient-centered out-
omes (eg, life expectancy, functional recovery, and major
dverse events) need to become the focus of studies high-
ighting the potential efficacy of endovascular therapy in the
horacic aorta. Previous reports have documented univari-
te predictors for short-term mortality after TEVAR20 but
re limited by small sample size and low event rates.
This analysis identifies independent risk factors associ-
ted with death within 1 year after TEVAR. These include
ge70 years, adjunctive intraoperative procedures, PAD,
VOD, CAD, and COPD, with a diagnosis of hyperlipid-
mia being protective. The model we have developed to
redict death within 1 year based on these covariates cor-
elates well with observed 1-year mortality rates in our
ample. Patients with multiple risk factors (4) have a very
igh predicted mortality before 1 year (54%), but those
ith zero risk factors have only 1% predicted 1-year mor-
ality.
An important point in this analysis is that most deaths
id not occur in the perioperative period (Fig 2). This
mphasizes the importance and utility of looking at other
utcome measures, such as 1-year mortality, to determine
rocedural efficacy. Nowygrod et al21 highlighted the ef-
ect of endovascular technologies on complication and
ortality profiles for a number of index peripheral vascular
perations but cautioned that endovascular interventions
re not always safer than their open counterparts, particu-
arly when compared over longer follow-up intervals. These
bservations detail the ongoing need for critical reassess-
ent of evolving technologies and the requirement for risktratification to guide clinical decision making.
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a useful counterpoint to the frequently cited annual rupture
or dissection risk of thoracic aortic aneurysms when discuss-
ing timing of repair. Although aneurysm diameter is a
somewhat imprecise variable for rupture risk prediction, as
highlighted in the infrarenal aorta,22 an accepted estimate
for rupture and dissection risk in DTA patients with an
aneurysm size of 6 to 6.5 cm is10% to 14% per year.10,23
Although current practice guidelines recommend repair in
patients with aneurysms 6.0 cm,18 our study highlights
specific populations of patients whose 1-year mortality rate
is much greater than 10% to 14% if they undergo repair.
Interestingly, our data suggest that surgeons at our insti-
Fig 3. Kaplan-Meier curve shows 1-year survival after
thoracic aneurysm (DTA) stratified by risk factor grou
log-rank test.
Fig 4. Predicted and actual mortality within 1 year after thoracic
endovascular aortic repair (TEVAR) is shown stratified by risk
factor group. The C index of the multivariable model for mortality
within 1 year of TEVAR was satisfactory at 0.77, and calibration of
the model was assessed by determination of the slope of a plot of
predicted vs observed events and found to be acceptable with a
slope of 0.94 and an intercept of 0.6% (slope of 1 and intercept of
0 representing perfect calibration).tution are already taking these factors into consideration— tffering low-risk patients repair at a mean diameter of 5.5
m and the highest-risk patients repair at an average diam-
ter of 7.0 cm (Fig 5). This indicates that we are probably
aiting longer to offer elective repair to sicker patients or
re using a higher threshold for risk of rupture or dissection
efore offering repair. When estimated annual rupture and
issection risk is compared with predicted mortality risk
ithin 1 year for each risk factor grouping, it appears that
atients with multiple risk factors should perhaps have
arger-diameter aneurysms before repair to justify risk and
enefit of the operation (Fig 6).
Another interesting finding within our analysis was the
ffect of hyperlipidemia on patient mortality. For the entire
atient cohort, 49% of the patients were taking a statin
rug; however, for those patients with a diagnosis of hyper-
ipidemia, the use of statins (79%) correlated well with the
ate of hyperlipidemia diagnosis (P .0005). This suggests
cic endovascular aortic repair (TEVAR) for descending
e defined risk factor groups were compared with the
ig 5. The mean thoracic aortic aneurysm diameter at repair
emonstrated a linear upward trend when patients were stratified
y risk factor group, suggesting a higher threshold for repair in
igher-risk patients.thora
p. Thhat the finding of hyperlipidemia as being protective may
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have documented the pleiotropic benefits of statin therapy
in the treatment of pathology localized to the extracranial
carotid, coronary, infrarenal aortic, and lower extremity
arterial beds.24-28 This was an unexpected finding in this
study, and interpreting the results would be presumptive
owing to the nature of the diagnosis of hyperlipidemia
determined from medical record review and not a biochem-
ical diagnosis, along with many other confounding issues
with statin therapy. The statin variable was not prospec-
tively recorded, and data for this variable were missing in
21% of the patients, so it was not incorporated into the
predictive model. Further studies will be needed to deter-
mine if statins or hyperlipidemia confer survival benefit in
DTA patients.
There are several limitations to this study, including the
retrospective, single-center nature of the inquiry and the
inherent selection bias that exists in this type of analysis. No
standardized treatment protocol was implemented during
the study interval, so the effect of aneurysm diameter and
the constellation of patient comorbidities on individual
surgeon decision making cannot be readily defined.
Furthermore, despite a novel description of a preoper-
ative prediction model for death within 1 year after elective
TEVAR for DTA, the reported estimation of this model’s
discrimination and calibration are inherently optimistic as-
sessments based on the original derivation data set. Exter-
nal validation in a multicenter cohort or registry data set, or
both, is mandatory before broader application in routine
clinical practice. The data analysis relied on several defini-
tions to document patient comorbidities, and the severity
and resulting clinical effect is not readily known from this
Fig 6. Thoracic aortic aneurysm diameter at the time of
compared with the predicted 1-year mortality after TEVA
the estimated yearly risk of aortic complications may no
diameters.type of data abstraction. SIn addition, no open surgical counterpart was reported
uring the same interval, so comparisons are not possible.
ltimately, perioperative decision making is individualized
o the patient, so use of a predictive model only serves to
nform the physician–patient discussion but not to make
efinitive decisions.
ONCLUSIONS
Death within 1 year of elective TEVAR likely represents
n unnecessary or ineffective therapy. It is important to
ote that most deaths within 1 year of TEVAR do not occur
n the perioperative period. Multiple factors available in the
reoperative setting are associated with death before 1 year
fter TEVAR and can be used for preoperative decision
aking and patient counseling. Patients with any combi-
ation of four or more independent predictors of 1-year
ortality have a predicted mortality of 50%. Therefore,
lder and sicker patients may be best served by waiting for
larger aneurysm size to justify the risk of the procedure.
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Dr Hazim J. Safi (Houston, Tex). I thank Adam Beck, MD,
for sending me this manuscript well in advance. The authors
have developed a prediction model for 30-day and 1-year mor-
tality after thoracic endovascular aortic repair (TEVAR). It is an
important contribution to our vascular literature. Most sur-
geons make this assessment (implicitly) when deciding on how
to manage patients with aneurysms. I congratulate the authors
for quantifying the relationship between the risk factors and
mortality rate. However, I wish that the authors had conduc-
ted an analysis to evaluate the effect of known statin use on
the hazard ratio. This might provide some assistance in inter-
preting the otherwise paradoxical findings. I have three ques-
tions:
1. Why didn’t the authors use the effective glomerular filtration. Can the authors elaborate on the incidence of neurological
deficit, stroke, paraplegia or paraparesis, and its impact on
mortality rate?
. Can the authors establish the need for adjunct procedures
preoperatively?
I thank the authors for their beautifully written manuscript
nd advances in our understanding of the risk factors that are
resent in TEVAR.
Dr Adam W. Beck. Thank you, Dr Safi. With regard to your
rst question regarding using the estimated glomerular filtration
ate (eGFR) rather than creatinine, we have preoperative creatinine
n our database, so that was the value that we used for the analysis.
owever, I do agree that eGFR would be a more accurate descrip-
ion of the patients’ renal function. We used a fairly strict definition
or renal insufficiency, with a creatinine of1.8, and perhaps using
t
v
p
p
s
p
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Volume 56, Number 5 Scali et al 1273eGFR might allow us to find an association with renal function and
1-year mortality.
In terms of the neurological complications of TEVAR and
how they affect outcome after surgery, this project was meant to
look at preoperative predictors of mortality, so we did not include
operative complications in the model. Spinal cord ischemia after
TEVAR is an academic interest to our group, and we have lookedhat complication after TEVAR profoundly negatively affects sur-
ival.
Regarding whether we can predict the need for adjunctive
rocedures preoperatively, the answer is yes and no. I think we can
redict the majority of the adjunctive procedures, such as carotid
ubclavian bypass, endo, or open conduits, as well as chimneys
erformed to create proximal and distal landing zones. However,at the effect that it has on mortality. Our rate of spinal cord
ischemia is about 9%, with a permanent deficit in 4%, and having
there were some adjunctive procedures that were performed based
on intraoperative decision making.
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